Motognosis announced getting funded by IBB Ventures and Athenion GmbH

Germany Investments 21 January 2021
Share on FacebookShare on Twitter

Motognosis, a Berlin, Germany-based healthcare SAAS developer for the independent measurement of symptoms by patients at home, announced that it completed a capital funding round.

The money was raised from investors from Germany IBB Ventures and Athenion GmbH.

Motognosis, founded in 2014 as a technology transfer startup from the NeuroCure Clinical Research Center of Charité Berlin. The company develops software solutions for the independent measurement of symptoms by patients at home. The focus is on the motor symptoms in neurological diseases such as Parkinson's disease or multiple sclerosis. The aim is to inform doctors and therapists quickly and accurately about the course of symptoms, and thus to enable patients to have access to medical experts, individual therapies and the best possible care.

The Motognosis measurement solution has already been validated in studies with more than 1,000 patients and is currently being used in research at 10 university hospitals. AMSA is certified as a medical measuring device according to MDD class Im and is now being launched on the market as an intervention solution.